Dmard

The risk-benefit profile of upadacitinib for rheumatoid arthritis “remains favorable” through 5 years, according to data published in The Journal of Rheumatology.

Bimekizumab treatment for psoriatic arthritis demonstrated rapid, clinically meaningful improvements to patient reported outcomes that were sustained up to 1 year, according to data published in Rheumatology.

Nearly 40% of children with oligoarticular juvenile idiopathic arthritis treated with intra-articular corticosteroids required no additional therapy, according to data published in Arthritis Research & Therapy.

Gut microbiota profiles in stool samples of patients with rheumatoid arthritis predicted their response to disease-modifying antirheumatic drugs, according to data in Rheumatology.

Among patients with rheumatoid arthritis diagnosed with breast cancer, the utilization of TNF inhibitors and other biologic disease-modifying antirheumatic drugs has not risen for more than a decade, according to data published in Arthritis Care & Research.

In this video, Sebastian E. Sattui, MD, MS, discusses the efforts needed to increase awareness of polymyalgia rheumatica.

SAN DIEGO — TNF inhibitors demonstrate comparable risks for hospitalization and death vs. non-TNF agents in patients with rheumatoid arthritis-associated interstitial lung disease, according to data presented at ACR Convergence 2023.

SAN DIEGO — Split-dose methotrexate had greater efficacy and reduced the need for additional disease-modifying antirheumatic drugs at 16 weeks vs. a single dose for rheumatoid arthritis, according to data presented at ACR Convergence 2023.

Little evidence suggests that any specific biologic or targeted synthetic disease-modifying antirheumatic drug is superior to another for rheumatoid arthritis, highlighting the importance of individualized treatment, according to data.